Robert G. Shawah - 29 Jun 2021 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Role
Chief Financial Officer
Signature
/s/ Kostantinos Skordalos, Power of Attorney For: Robert G. Shawah
Issuer symbol
ACXP
Transactions as of
29 Jun 2021
Transactions value $
$0
Form type
4
Filing time
06 Jul 2021, 16:06:23 UTC
Previous filing
24 Jun 2021
Next filing
24 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACXP Stock Option Award $0 +70K $0.00 70K 29 Jun 2021 Common Stock 70K $6.26 Direct F1
transaction ACXP Stock Option Award $0 +200K $0.00 200K 01 Jul 2021 Common Stock 200K $6.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 29, 2021 (the "June Grant Date"), the Reporting Person was granted stock options to purchase 70,000 shares of the Issuer's common stock. 40% of the stock options granted became vested and exercisable on the June Grant Date and 60% of the stock options shall become vested and exercisable as of each monthly anniversary from the June Grant Date, such that all stock options shall be fully vested and exercisable by June 29, 2024. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.
F2 On July 1, 2021 (the "Employment Agreement Grant Date"), the Reporting Person was granted stock options to purchase 200,000 shares of the Issuer's common stock in connection with the Reporting Person's service as the Issuer's Chief Financial Officer pursuant to the Reporting Person's employment agreement. 25% of the stock options granted became vested and exercisable on the Employment Agreement Grant Date and 75% of the stock options shall become vested and exercisable as of each monthly anniversary from the Employment Agreement Grant Date, such that all stock options shall be fully vested and exercisable by July 1, 2024.

Remarks:

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.